CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 8-10 weeks | $ 1024 | |
10 mg | 8-10 weeks | $ 1945 | |
20 mg | 8-10 weeks | $ 2723 | |
50 mg | 8-10 weeks | $ 5167 | |
100 mg | 8-10 weeks | $ 7750 |
Description | CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively. |
Targets&IC50 | CTX,CCR4 antagonist 2:70 nM , Ca2+flux:40 nM |
CAS No. | 2206788-99-8 |
Chemical Formula | C26H28Cl2N6O |
Molecular Weight | 511.45 |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom